The role of comorbidities in chronic myeloid leukemia

被引：6

作者：

Breccia, Massimo ^{[1
]}

Alimena, Giuliana ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy

来源：

LEUKEMIA RESEARCH | 2013年 / 37卷 / 07期

关键词：

Chronic myeloid leukemia; Tyrosine kinase inhibitors; Comorbidities; PULMONARY ARTERIAL-HYPERTENSION; OCCLUSIVE DISEASE; CO-MORBIDITY; FOLLOW-UP; DASATINIB; IMATINIB; NILOTINIB;

D O I：

10.1016/j.leukres.2013.04.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：729 / 730

页数：2

共 16 条

[1]

Breccia M, 2012, CRIT REV ONCOL HEMAT

[2] Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: Who's afraid of the big bad wolf? [J].

Breccia, Massimo ;

Efficace, Fabio ;

Alimena, Giuliana .

LEUKEMIA RESEARCH, 2012, 36 (07) :813-814

[3] Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients [J].

Breccia, Massimo ;

Alimena, Giuliana .

BIODRUGS, 2011, 25 (03) :147-157

[4] Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development [J].

Breccia, Massimo ;

Alimena, Giuliana .

EXPERT OPINION ON DRUG SAFETY, 2010, 9 (05) :713-721

[5] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].

CHARLSON, ME ;

POMPEI, P ;

ALES, KL ;

MACKENZIE, CR .

JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383

[6] Mechanisms of resistance to BCR--ABL kinase inhibitors [J].

Diamond, Joana M. ;

Melo, Junia V. .

LEUKEMIA & LYMPHOMA, 2011, 52 :12-22

[7] PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE [J].

FEINSTEIN, AR .

JOURNAL OF CHRONIC DISEASES, 1970, 23 (07) :455-+

[8] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study [J].

Giles, F. J. ;

le Coutre, P. D. ;

Pinilla-Ibarz, J. ;

Larson, R. A. ;

Gattermann, N. ;

Ottmann, O. G. ;

Hochhaus, A. ;

Radich, J. P. ;

Saglio, G. ;

Hughes, T. P. ;

Martinelli, G. ;

Kim, D-W ;

Novick, S. ;

Gillis, K. ;

Fan, X. ;

Cortes, J. ;

Baccarani, M. ;

Kantarjian, H. M. .

LEUKEMIA, 2013, 27 (01) :107-112

[9]

Giles F.J., 2012, LEUKEMIA

[10] Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) [J].

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Issaragrisil, Surapol ;

Clark, Richard E. ;

Reiffers, Josy ;

Nicolini, Franck E. ;

Pasquini, Ricardo ;

Kalaycio, Matt ;

Hughes, Timothy P. ;

Hochhaus, Andreas ;

Kemp, Charisse ;

Fan, Xiaolin ;

Waltzman, Roger J. ;

Saglio, Giuseppe ;

Larson, Richard A. .

BLOOD, 2012, 120 (21)

← 1 2 →